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of 16 criteria. Methods: 85 experts were interviewed to estimate the importance 
of each criterion in the decision-making on financing MT for rare diseases. We 
used 10-point scale, where 10 points mean major importance to the priority indica-
tor, and 1point means minor importance. Mean estimates were calculated using 
descriptive statistics, then means were normalized. Results: Respondents were 
41 years on average (ranging from 23 to 64 years), and included 20 public servants, 
16 health administrators, 32 practitioners, and 14 researchers. 44 respondents had 
a scientific degree. The most important criteria were characteristics of treatment - 
“Effect of treatment on quality of life” and “Effect of treatment on life expectancy” 
with 1 points each. The least important criteria were both characteristics of the 
disease - “Cognitive disorders as manifestations of the disease and “Additional bur-
den on the daily lives of care-givers” with 0.28 and 0.1 respectively. ConClusions: 
Characteristics of treatment turned out to be more important for respondents than 
characteristics of disease, therefore characteristics of treatment should be given 
consideration when evaluating rare diseases to determine priority financing.
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objeCtives: Opioid analgesics are proven to be safe and effective in malignant or 
nonmalignant pains. The consumption trend of six opioids (Morphine, Codeine, 
Oxycodone, Fentanyl, Pethidine, and Methadone) in Islamic Republic of Iran 
assumed as an indicator for prescription pattern and is evaluated during five year 
period (2007-2011) as the aim of this study. Methods: The data of opioid analgesic 
consumption were collected from FDO (Food and Drug Organization) of Iran. The 
collected data were converted to DDD (Define Daily Dose) for each of six selected 
opioids in order to be compared accurately. Results: Overall consumption of opi-
oids was grown during the period of investigation. Putting six selected opioids into 
two groups – synthetic and non-synthetic -, the growth rate of synthetic ones are 
obviously higher than those of non-synthetics. Opioid analgesics consumption in 
2011 was shown to be 4 times more than the opioid consumption in 2007. The CAGR 
(Compound Average Growth Rate) between 2007-2011 were reported 111.27%, 33.11%, 
16.48%, 3.91%, 3.76%, and -41.63% for Oxycodone, Methadone, Fentanyl, Morphine, 
Pethidine and Codeine respectively. The growth rate of mentioned above opioids 
for the last year of investigation was reported 41.12%, 16.54%, 29.99%, -0.38%, 7.66%, 
23.67% respectively. ConClusions: Like other low consuming countries, consump-
tion of opioid analgesics in Iran is limited by means of different kinds of barriers. 
There are also parameters which set a specific orientation in opioid consumption. 
Analyzing this trend, results in defining the barriers and other parameters clearly.
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objeCtives: In Europe, orphan designation has been granted by European 
Medicines Agency since 2000. Molecules with orphan designation can benefit from 
a number of incentives to guarantee return on investment for manufacturers. Since 
introduction of orphan legislation, the number of Orphan Drugs (OD) has signifi-
cantly increased. In 2012, total OD sales reached 13% of the whole pharmaceutical 
market. This study aims to analyse current situation and trends in OD approv-
als. Methods: All ODs approved gaining marketing authorization was identified 
through EMA website. Extensions to a new disease were considered as an independ-
ent approval, while extensions of indication for the same condition were not consid-
ered. Information on drug status, indications, therapeutic area, and authorisation 
date was extracted. Results: 77 orphan molecules were identified of which two 
have been withdrawn, and one orphan designation has expired. Yearly approvals 
continuously grow (from 2 ODs approved in 2002 to 12 and 8 drugs in 2012 and 2013 
respectively). By mid-2014, already 6 were approved. There is a high imbalance 
within therapeutic area with 36% for oncology, 27% for endocrine, nutritional and 
metabolic disorders whereas the remaining 37% cover 11 therapeutic classes. No 
product has been approved for 7 therapeutic areas despite existence of rare disor-
ders. Moreover, oncology is associated with the highest growth. ConClusions: 
Orphan drug market is rapidly growing but targeting selective therapeutic areas 
with high potential return on investment. The incentive policies happen to well 
function but discriminate among diseases. A review of orphan drug policies might 
be warranted to ensure patient equity in development of new OD.
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objeCtives: While there exist a number of incentives to stimulate research and 
development of orphan drugs (OD), the Health Technology Assessment (HTA) agen-
cies do not offer specific path for OD in most countries where it is left to payer value 
judgement. This leads to a high inequity in patient access to OD. The study aims 
at comparing the HTA decisions, price and reimbursement level of OD in France 
and Italy. Methods: All OD assessed since 2000 were analysed. Prices, reimburse-
ment rates and decision details were extracted for each drug using Farmadati Italia 
database for Italy and Transparency committee reports, AMELI’s national health 
insurance and Thériaque databases for France. Results: Among 74 OD approved in 
Europe 66 are available in Italy compared to 53 in France. All ODs available in France 
are officially available in Italy. The average delay between the market authorization 
and the price and reimbursement decision was about 16 and 17 months in France 
and Italy, respectively. In France all available drugs are 100% reimbursed through 
hospital, 36 molecules are available in retail pharmacy with reimbursement from 
time, medical/surgical complications to refine a robust measure of effectiveness 
useful to perform cost effectiveness analysis.
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objeCtives: To assess the characteristics of SLE patients currently on Remission 
(Group-1), currently with active disease but not experiencing a flare (Group-2) and 
those who are experiencing flares (Group-3) in Europe (EU). Methods: A multi-
center medical chart review of adult (16-89 yrs) SLE patients was conducted in 
1Q2014 among rheumatologists/internal medicine physicians in UK/France/
Germany/Italy/Spain (5EU). Physicians were recruited from a geographically repre-
sentative sample in each country. Approx. 5 consecutive eligible persistent active or 
relapse remitting SLE patients currently managed as part of usual care were identi-
fied. Physicians abstracted de-identified patient data on disease characteristics, lab 
values and treatment patterns. Patient disease status and humanistic burden was 
assessed by physician per clinical judgment & patient interaction. Results: 747 SLE 
patient charts were abstracted in 5EU (UK: 156/France: 149/Germany: 148/Italy: 146/
Spain: 148); Group-1: 25.7% (range: 19.9% (Italy) –29.7% (Germany)), Group-2: 56.2% 
(range: 42.3% (UK) –66.4% (Italy)), Group-3: 18.1% (range: 13.5 (Germany) –28.8 (UK)). 
Patient characteristics included (Group-1/Group-2/Group-3): age (yrs): 41.4/43/40.6; % 
female: 81.8/80.2/77.8; % full-time employment: 38.0/34.5/32.6; % part-time employ-
ment: 25.5/20.5/17.8; % on sick leave: 3.6/7.6/17.0; % currently receiving treatment 
in in-patient setting: 3.1/7.6/28.1; % hospitalized > = 1 in past-year: 23.4/32.1/55.6. 
Top-5 organ manifestations were (% Group-1/Group-2/Group-3): musculoskeletal: 
90.6/89.5/88.1, mucocutaneous: 86.5/84.0/85.2, haematologic: 45.8/53.8/55.6, renal: 
23.4/26.7/33.3, pulmonary: 15.1/13.6/26.7. In Group-1/Group-2/Group-3, % patients 
with low C3 and C4 were 33.3/53.9/73.4 and 31.6/53.2/77.5 and % anti-ds-DNA posi-
tive were 54.7/71.0/78.5. Humanistic burden (reported via physician ratings, on a 
scale of 0 (most impact) to 7 (least impact)) was (Group-1/Group-2/Group-3, mean 
scores): patient ability to perform every-day tasks: 6.11/5.17/4.37, patient ability to 
interact fully with family and friends: 6.20/5.45/4.90, and patient ability to work/
keep employment: 5.76/4.80/3.87. ConClusions: Over half of the SLE patients had 
an active disease while one-in-five were experiencing a flare in this study cohort, 
with significant variations observed within 5EU. Clinical and humanistic burden 
varied based on patient disease status, with highest burden observed among those 
experiencing flares.
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objeCtives: Despite increasing policy guidance to encourage the development 
of and access to orphan drugs, the policy landscape indicates a lack of transpar-
ency and consistency across countries. The objective of this study is to compare 
the orphan drug policies of Japan, South Korea, and Taiwan to the policies in the 
EU. Methods: A targeted literature review was conducted to identify papers per-
taining to orphan drugs in Japan, South Korea and Taiwan, with a focus on quantita-
tive analysis for policy-making related to pricing and reimbursement from the payer 
perspective. No limits were placed on language. Country specific policy websites 
were hand-searched. Results: A total of 3465 abstracts were identified for screen-
ing. Of those, 104 were eligible for full-text screening. The definition of prevalence 
with regard to rare diseases in Japan, South Korea and Taiwan was stricter than in 
the EU. All of them had introduced regulations, guidelines and incentives to the 
development of orphan-designated drugs. Strict HTA requirements were waived 
for rare diseases, although cost-effectiveness data are referenced in South Korea. 
In Japan and Taiwan, prices were reduced for existing drugs with new orphan-
designated indications. Within the existing benefits of national health insurance 
schemes or under the coverage of rare disease regulations, full reimbursement 
was given, which is different from the partial reimbursements observed in cer-
tain European countries. In some cases, the application of drug treatment can be 
approved prior to or without market authorisation. The availability of orphan drugs 
to patients was not inferior to that of the EU. ConClusions: While access in Japan, 
South Korea and Taiwan is seemingly no different to the EU, there are no consistent 
or transparent policies in place in these countries. Policy makers should prepare 
innovative schemes that offer warranties to both payers and patients and establish 
a systematic evaluation procedure for manufacturers.
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objeCtives: The ranking and prioritization of rare diseases are crucial in order to 
define for which of them state support measures are justifiable. For this purpose the 
set of 16 criteria to assess rare diseases (8 related to the characteristics of disease, 
and 8 to the characteristics of treatment) was proposed by experts, so multi-criteria 
decision (MCDA) analysis approach could be useful. The aim of the study was to 
assess the reliability of the criteria set and to determine the relative importance 
